Blood pressure medication recalled nationwide under FDA’s Class II risk level

Live updates

1. 2d ago

   Nationwide Blood Pressure Medication Recall Expands

   Macleods Pharma USA has recalled thousands of bottles of a prescription three-drug blood pressure medication across the United States. The Food and Drug Administration classified the action as a Class II risk level after the products failed dissolution tests. A total of 3,744 bottles of the prescription medication are affected by the nationwide action. Patients are advised to check specific lot numbers and consult a pharmacist before stopping their medication. This recall expands ongoing pharmaceutical industry actions involving multiple manufacturers over quality and potency concerns.

   Why it matters

   Dissolution testing failure means a medication may not break down correctly in the body, potentially impacting how the drug is absorbed and whether it effectively controls blood pressure. The Food and Drug Administration maintains databases tracking thousands of drug recalls to help consumers verify affected products by name, lot number, or company. This incident adds to a broader pattern of pharmaceutical recalls affecting multiple manufacturers across the country.

   What is confirmed

   • Macleods Pharma USA recalled thousands of bottles of a prescription three-drug blood pressure medication nationwide.
   • The Food and Drug Administration classified the recall as a Class II risk level.
   • The recall was initiated after products failed dissolution tests.
   • A total of 3,744 bottles of prescription blood pressure medication are affected by the recall.

   Still unconfirmed

   • OpenFDA records contain a total of 18,080 to 18,113 drug recalls, with updates noted as recently as November 9, 2026.

   What to watch next

   • Additional lot numbers added to the Macleods Pharma USA recall by the Food and Drug Administration
   • Further updates regarding industry-wide investigations into blood pressure medication dissolution failures
   Sources used for this update (3)

   1. rxrecalls.com — Check if your medication has been recalled | RxRecalls
   2. blusherme.com — Blood Pressure Pills Recalled Nationwide After Failing Tests ...
   3. livehealth.store — Drug Recalls 2026: Latest FDA List | Live Health
   confidence 100%
2. 5d ago

   Macleods Pharma Recalls Blood Pressure Pills Nationwide

   Macleods Pharma USA has recalled thousands of bottles of a prescription three-drug blood pressure medication across the United States. The Food and Drug Administration classified the action as a Class II risk level following failed dissolution tests. Patients are advised to check specific lot numbers and consult a pharmacist before discontinuing their medication. This action expands ongoing pharmaceutical industry recalls affecting multiple manufacturers over quality and potency concerns.

   Why it matters

   Failed dissolution tests indicate that medications may not release active ingredients into the body correctly, risking improper treatment control. The nationwide recall affects thousands of bottles distributed by Macleods Pharma USA. This development builds on prior regulatory actions involving multiple manufacturers and various blood pressure medications.

   What is confirmed

   • Macleods Pharma USA recalled 3,744 bottles of a three-drug blood pressure medication.
   • The Food and Drug Administration classified the Macleods Pharma recall as a Class II risk level.
   • The medication failed dissolution specifications during testing.

   What to watch next

   • Additional lot number expansions from Macleods Pharma USA
   • Further Food and Drug Administration enforcement actions regarding blood pressure medications
   Sources used for this update (4)

   1. www.futuremarketinsights.com — Stretch Films Market Size, Share, Trends 2036
   2. www.medicaldaily.com — Macleods Recalls 3,744 Bottles of Three-in-One Blood Pressure ...
   3. www.goodhousekeeping.com — FDA Announces Another Blood Pressure Medication Recall ...
   4. capitaldigest.com — Blood Pressure Pills Recalled: 3,700+ Bottles Fail Tests
   confidence 100%
3. 8d ago

   FDA upgrades recall of blood pressure medication to Class II risk

   The FDA has upgraded the recall of certain blood pressure medications to a Class II risk level due to quality failures, superpotency issues, and impurity risks. Teva Pharmaceuticals recalled nearly 581,000 bottles of prazosin hydrochloride capsules, and Macleods Pharma USA recalled thousands of bottles of prescription blood pressure medication. These actions follow earlier recalls by Vitaris and Inventia Healthcare Limited involving telmisartan, amlodipine, and chlorthalidone tablets.

   Why it matters

   The recalls are nationwide and involve various blood pressure medications. The FDA monitors and manages these recalls due to potential health risks associated with the quality issues. Elevated levels of impurities, such as N-nitroso prazosin, have been detected in some medications.

   What is confirmed

   • Teva Pharmaceuticals recalled nearly 581,000 bottles of prazosin hydrochloride capsules.
   • The recall was upgraded to a Class II risk level by the FDA.
   • Elevated levels of N-nitroso prazosin were detected in prazosin hydrochloride capsules.

   What to watch next

   • Further updates on the recall by the FDA
   • Potential health impacts of the recalled medications
   • Additional recalls of blood pressure medications
   Sources used for this update (2)

   1. dmbio.com — What Blood Pressure Medication Was Recalled in November 2026?
   2. www.rd.com — Blood Pressure Medication Bottles Recalled as Risk Level Rises
   confidence 100%
4. 10d ago

   Nationwide Blood Pressure Medication Recalls Expand Across US

   Federal health regulators are managing expanded nationwide recalls of blood pressure medications due to quality failures, superpotency issues, and impurity risks. Teva Pharmaceuticals voluntarily pulled nearly 581,000 bottles of prazosin hydrochloride capsules after detecting elevated levels of the potentially cancer-causing impurity N-nitroso prazosin above acceptable limits. Meanwhile, Macleods Pharma USA recalled thousands of bottles of prescription blood pressure medication after the Food and Drug Administration reported failures to meet dissolution specifications. These actions follow earlier recalls by Vitaris and Inventia Healthcare Limited involving telmisartan, amlodipine, and chlorthalidone tablets.

   Why it matters

   The Food and Drug Administration monitors drug manufacturing to ensure treatments maintain correct potency and safety standards. Dissolution testing failures and excessive drug components can alter how medications perform in the body, creating risks of ineffectiveness or adverse health consequences. Impurities like N-nitroso prazosin further complicate pharmaceutical safety oversight.

   What is confirmed

   • Teva Pharmaceuticals voluntarily recalled nearly 581,000 bottles of prazosin hydrochloride capsules due to elevated levels of N-nitroso prazosin.
   • Macleods Pharma USA recalled thousands of bottles of prescription blood pressure medication after failing dissolution specifications.
   • The Food and Drug Administration cited failure to meet dissolution standards, referring to how a tablet dissolves during testing.

   Still unconfirmed

   • Prazosin hydrochloride capsules are used primarily to treat high blood pressure and prostate conditions and sometimes off-label for PTSD symptoms.

   What to watch next

   • Additional regulatory classifications by the Food and Drug Administration regarding the Macleods Pharma USA and Teva Pharmaceuticals recalls.
   • Further voluntary product withdrawals from pharmaceutical manufacturers.
   Sources used for this update (8)

   1. www.foxbusiness.com — Great Business Leaders in America & Around the World | Fox Business
   2. www.newsbreak.com — Cathie Wood Predicts Oil Crashing to $30-$35 a Barrel as EVs Take Over Transportation: Says Demand Is 'Peaking’
   3. www.ntd.com — Blood Pressure Drug Recalled Nationwide for Failing Quality ...
   4. 3bmedianews.com — OVER 581,000 BOTTLES OF BLOOD PRESSURE MEDICATION RECALLED
   5. www.research.va.gov — VA Research News Briefs
   6. www.foxbusiness.com — Blood pressure medicine recall: Thousands of bottles pulled ...
   7. www.ktbs.com — FDA classifies nationwide recall of blood pressure medication ...
   8. kfyi.iheart.com — Blood Pressure Medication Recalled Nationwide Over Quality ...
   confidence 95%
5. 15d ago

   Nationwide Blood Pressure Medication Recalls Affect Thousands of Bottles

   Federal health regulators have issued nationwide recalls for multiple blood pressure medications due to superpotency issues and failing safety testing. Vitaris is recalling nearly 22,000 bottles of generic telmisartan and amlodipine tablets in 40-milligram and 5-milligram doses. Additionally, Inventia Healthcare Limited initiated a voluntary recall for chlorthalidone 25 mg tablets because of dissolution testing failures. The Food and Drug Administration assigned a Class II risk level to the chlorthalidone action, warning that affected pills contain excessive drug components and may cause temporary adverse health consequences. Some batches of the medication contain too much telmisartan according to recent agency warnings.

   Why it matters

   The Food and Drug Administration issued the recall actions earlier in October. These regulatory steps address manufacturing and testing failures that compromise how blood pressure treatments work in patients. Consumers are advised to check their medicine cabinets for the affected products.

   What is confirmed

   • The Food and Drug Administration issued the recall earlier in October.
   • Vitaris is recalling nearly 22,000 bottles of generic telmisartan and amlodipine tablets in 40-milligram and 5-milligram doses.
   • Inventia Healthcare Limited initiated a voluntary nationwide recall for chlorthalidone 25 mg tablets following failures in safety and dissolution testing specifications.
   • The Food and Drug Administration designated the chlorthalidone action under a Class II risk level.

   Still unconfirmed

   • Medication may not work exactly as desired due to evidence found in a new report.

   What to watch next

   • Additional risk classifications from the Food and Drug Administration
   • Expansion of the affected lot numbers by Vitaris or Inventia Healthcare Limited
   • Specific instructions for consumers returning recalled bottles to pharmacies
   Sources used for this update (4)

   1. www.yahoo.com — Over 20,000 Bottles of Blood Pressure Medication Recalled ...
   2. www.express.co.uk — Urgent blood pressure drug recall issued over 'super potent ...
   3. sideeffectsbase.com — FDA Drug Recall List 2026: How to Check Your Medication
   4. www.thehealthy.com — FDA: More Than 3,000 Bottles of Blood Pressure Drug Recalled ...
   confidence 95%
6. 18d ago

   Blood Pressure Medications Recalled Nationwide For Excess Superpotency

   Multiple blood pressure medications are subject to nationwide recalls due to risks involving excess superpotent drug components. Vitaris is recalling nearly 22,000 bottles of generic telmisartan and amlodipine tablets in 40-milligram and 5-milligram doses because of superpotency issues. Additionally, Inventia Healthcare Limited initiated a voluntary nationwide recall for chlorthalidone 25 mg tablets following failures in safety and dissolution testing specifications. Food and Drug Administration officials indicate that the chlorthalidone tablets could contain superpotent elements. The agency designated the chlorthalidone action under a Class II risk level, which indicates that the product may cause temporary adverse health consequences.

   Why it matters

   Drug recalls of this nature carry significant public health implications because variations in medication potency can lead to unintended therapeutic effects or adverse reactions in patients managing chronic conditions like hypertension. Regulatory bodies track these safety failures to prevent patient exposure to substandard pharmaceuticals. The intersection of manufacturing defects and potency testing failures highlights ongoing quality control challenges within the generic drug supply chain.

   What is confirmed

   • Blood pressure medication sold nationwide was recalled due to the potential of excess superpotent drug.

   Still unconfirmed

   • Generic valsartan sold from 2012 to 2019 contained NDMA, a cancer-causing chemical, prompting ongoing federal lawsuits from cancer patients.

   What to watch next

   • Official updates from the FDA regarding expansion of the affected drug lots
   • Results from further dissolution and safety testing of recalled medication batches
   Sources used for this update (3)

   1. www.harmreport.com — Valsartan - Blood Pressure Drug & NDMA Recall (2026 Update)
   2. recalls.watch — Recall Check: Product, Food, Drug and Vehicle Recalls
   3. www.yahoo.com — Blood pressure medication recalled due to potential excess ...
   confidence 80%
7. 21d ago

   Vitaris Recalls Blood Pressure Medication Over Superpotency

   Vitaris is executing a recall for nearly 22,000 bottles of generic blood pressure medication due to superpotency issues. The affected products include tablets of telmisartan and amlodipine in 40-milligram and 5-milligram doses. Concurrently, Inventia Healthcare Limited is conducting a separate voluntary nationwide recall of chlorthalidone 25 mg tablets because the medication failed safety and dissolution testing specifications. Food and Drug Administration officials report that the chlorthalidone tablets could contain a superpotent element. The agency classified the chlorthalidone action as a Class II risk level, meaning the product may cause temporary adverse health consequences.

   Why it matters

   Drug recalls involving superpotent ingredients pose direct health risks to patients managing hypertension. These manufacturing discrepancies trigger regulatory interventions to remove compromised batches from the supply chain and protect consumers from adverse effects. The Food and Drug Administration oversees these safety classifications to mitigate potential harm.

   What is confirmed

   • Vitaris is recalling tablets of its generic telmisartan and amlodipine, in 40-milligram and 5-milligram doses.
   • Inventia Healthcare Limited is executing a voluntary nationwide recall of chlorthalidone 25 mg tablets because the blood pressure medication failed safety and dissolution testing specifications.
   • Food and Drug Administration officials report that the affected chlorthalidone medication could contain a superpotent element.
   • The Food and Drug Administration classified the chlorthalidone action as a Class II risk level, indicating the product may cause temporary adverse health consequences.

   Still unconfirmed

   • Nearly 22,000 bottles of blood pressure medication are involved in the Vitaris recall.

   What to watch next

   • Further Food and Drug Administration enforcement actions or expansion of the Vitaris recall.
   • Pharmacy-level verification and inventory reports for affected telmisartan and amlodipine supplies.
   Sources used for this update (2)

   1. www.fda.gov — Alerts, Advisories & Safety Information | FDA
   2. www.theepochtimes.com — Nearly 22,000 Bottles of Blood Pressure Medication Recalled ...
   confidence 90%
8. 24d ago

   Nationwide Blood Pressure Drug Recall Expands

   Inventia Healthcare Limited is executing a voluntary nationwide recall of chlorthalidone 25 mg tablets because the blood pressure medication failed safety and dissolution testing specifications. Food and Drug Administration officials report that the affected medication could contain a superpotent element. The agency classified this action as a Class II risk level, indicating the product may cause temporary adverse health consequences. Affected patients are advised to contact their pharmacist to verify their medication supply, while regulatory data shows broader industry quality issues.

   Why it matters

   Chlorthalidone medication is prescribed to keep blood pressure in check by decreasing water and salt in the body through an uptick in urine flow. This action follows other major pharmaceutical recalls, including Dr Reddy Laboratories Ltd pulling 13,560 bottles of metoprolol succinate. Regulatory scrutiny also involves separate safety alerts regarding valsartan, irbesartan, and losartan products contaminated with cancer-causing chemicals.

   What is confirmed

   • Inventia Healthcare Limited is executing a voluntary nationwide recall of chlorthalidone 25 mg tablets due to failing safety and dissolution testing specifications.
   • The Food and Drug Administration classified the chlorthalidone recall as a Class II risk level.
   • Chlorthalidone is a medication prescribed to keep blood pressure in check by decreasing water and salt in the body through an uptick in urine flow.

   Still unconfirmed

   • FDA officials state there is a chance the chlorthalidone medication could contain a superpotent element.

   What to watch next

   • Further statements from the FDA regarding the extent of the superpotent element in the chlorthalidone tablets
   • Additional guidance for patients affected by the nationwide recall of Inventia Healthcare Limited chlorthalidone
   Sources used for this update (3)

   1. www.yahoo.com — Yahoo
   2. www.thehealthy.com — Blood Pressure Drug Recall: More Than 21,000 Bottles Involved ...
   3. economictimes.indiatimes.com — nitrosamine: Latest News & Videos, Photos about nitrosamine ...
   confidence 90%
9. 27d ago

   Blood pressure medication recalls widen across United States

   Inventia Healthcare Limited is executing a voluntary nationwide recall of chlorthalidone 25 mg tablets because the blood pressure medication failed safety and dissolution testing specifications. The Food and Drug Administration classified this action as a Class II risk level, indicating the product may cause temporary adverse health consequences. Affected patients are advised to contact their pharmacist to verify their medication supply. Meanwhile, regulatory data shows broader industry quality issues, including a recall by Dr Reddy Laboratories Ltd involving 13,560 bottles of metoprolol succinate, and separate safety alerts concerning valsartan, irbesartan, and losartan products contaminated with cancer-causing chemicals.

   Why it matters

   Quality flaws among Indian pharmaceutical giants have triggered multiple US product recalls tracked by Food and Drug Administration data. These ongoing actions highlight persistent manufacturing standards challenges within the generic hypertension drug supply chain. Patients relying on these medications face repeated disruptions and potential health risks tied to substandard dissolution and chemical contamination.

   What is confirmed

   • Inventia Healthcare Limited initiated a voluntary nationwide recall of chlorthalidone 25 mg tablets after the medication failed safety and dissolution testing specifications.
   • The Food and Drug Administration classified the chlorthalidone recall under its Class II risk level for products that may cause temporary adverse health consequences.
   • Dr Reddy Laboratories Ltd recalled 13,560 bottles of metoprolol succinate in the United States.
   • Blood pressure drugs containing valsartan, irbesartan, and losartan were recalled due to possible contamination by cancer-causing chemicals.

   Still unconfirmed

   • Patients nationwide are actively experiencing widespread shortages due to the ongoing blood pressure medication recalls.

   What to watch next

   • Additional Food and Drug Administration classifications or expansions of the chlorthalidone and metoprolol succinate recalls.
   • Further manufacturer statements regarding contamination levels in valsartan, irbesartan, and losartan supplies.
   Sources used for this update (3)

   1. www.fda.gov — Drug Alerts and Statements | FDA
   2. toledolaw.com — Dr Reddy’s Recalls Generic Hypertension Drug | Zoll & Kranz
   3. toledolaw.com — Blood Pressure Drugs Containing Valsartan, Irbesartan, and ...
   confidence 95%
10. 30d ago

    FDA Class II Recalls Include Indian Pharma Products Over Quality Flaws

    Indian pharmaceutical giants are executing product recalls in the United States due to quality flaws, according to recent Food and Drug Administration data. The ongoing actions include a voluntary nationwide recall by Inventia Healthcare Limited of chlorthalidone 25 mg tablets after the blood pressure medication failed safety and dissolution testing specifications. The Food and Drug Administration classified the chlorthalidone action under its Class II risk level, which covers products that may cause temporary adverse health consequences. Patients using the medication are urged to contact their pharmacist to verify if their supply is affected.

    Why it matters

    The Food and Drug Administration tracks thousands of product recalls annually, categorizing actions by risk level to inform the public about safety hazards. Class II recalls indicate a moderate risk where the probability of serious health consequences is remote. Quality failures in medications such as blood pressure treatments present significant management challenges for patients who rely on consistent dosages.

    What is confirmed

    • The Food and Drug Administration classified the Inventia Healthcare Limited chlorthalidone recall under its Class II risk level.
    • Indian pharmaceutical giants are recalling medicines in the United States over quality flaws.

    What to watch next

    • Additional announcements regarding specific Indian pharmaceutical companies involved in United States recalls
    • Updated Food and Drug Administration lists containing lot numbers and product identifiers for affected drug supplies
    Sources used for this update (6)

    1. indiawest.com — FDA: Indian Pharma Giants Will Recall Medicines In US Over Quality ...
    2. recalldirectory.com — Recall Directory — Product Recalls from FDA, CPSC & NHTSA ...
    3. recalldirectory.com — Is My Product Recalled? - Recall Directory
    4. recallbench.com — Is it recalled? Search every U.S. recall by product, lot code ...
    5. recalldirectory.com — FDA Class II Recalls - Recall Directory
    6. www.regdatalab.com — FDA Recall Statistics 2026 — RegDataLab
    confidence 100%
11. 37d ago

    Inventia Healthcare Recalls Over 25,000 Bottles of Blood Pressure Pills

    Inventia Healthcare Limited is executing a voluntary nationwide recall of chlorthalidone 25 mg tablets after the medication failed safety and dissolution testing specifications. The Food and Drug Administration classified the ongoing action under its Class II risk level, indicating moderate risk. The recalled products treat high blood pressure and are occasionally prescribed for patients managing heart failure, kidney disease, or liver cirrhosis. Patients using the medication are urged to contact their pharmacist to check whether their supply is affected.

    Why it matters

    This enforcement action marks the manufacturer's second recall of the tablets this year. The affected pills failed laboratory safety tests, prompting federal regulators to categorize the risk level. Specific nationwide distribution locations for the impacted medication remain omitted from official enforcement reports.

    What is confirmed

    • Inventia Healthcare Limited issued a voluntary recall for 13,567 bottles of 25 mg chlorthalidone tablets.
    • The Food and Drug Administration classified the action under its Class II risk level.
    • The affected medication failed laboratory safety and dissolution tests.
    • The manufacturer's total recalled volume for the tablets has exceeded 25,027 bottles across two recalls this year.

    Still unconfirmed

    • Patients are being urged to contact their pharmacist to verify if their specific medication is affected by the recall.

    What to watch next

    • Release of specific nationwide distribution locations for the impacted bottles by the FDA.
    • Further statements from Inventia Healthcare Limited regarding the root cause of the laboratory test failures.
    Sources used for this update (8)

    1. medivascan.com — Drug recalls, by class and condition - MedivaScan
    2. drugrecallcheck.com — Check if your medication has been recalled | US Drug Recall ...
    3. medivascan.com — Blood pressure medication recalls | MedivaScan
    4. www.aol.com — FDA Issues Class II Blood Pressure Medication Recall, Over 13,000 Bottles Affected - AOL
    5. www.yahoo.com — Blood pressure medication recall expands as more ... - Yahoo
    6. www.express.co.uk — Blood pressure drug urgently recalled after common tablet ...
    7. www.dailystar.co.uk — Blood pressure pills urgently recalled after failing safety ...
    8. cleanandrecovery.com — Blood Pressure Medication Recall: What to Check Now
    confidence 95%
12. 39d ago

    Nationwide Blood Pressure Medication Recall Underway

    Inventia Healthcare Limited is executing a nationwide voluntary recall for 13,567 bottles of chlorthalidone 25 mg tablets because the medication failed dissolution testing specifications. The Food and Drug Administration classified this ongoing action under its Class II risk level on September 17. The affected pills treat high blood pressure and are sometimes prescribed for patients managing heart failure, kidney disease, or cirrhosis of the liver. An enforcement report confirmed the Class II designation, though it omitted specific nationwide distribution locations for the impacted medication.

    Why it matters

    Class II risk level recalls involve situations where the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences. Dissolution testing ensures that medications release their active ingredients correctly inside the body. Failures in these specifications can lead to improper dosing and ineffective treatment for chronic conditions like hypertension.

    What is confirmed

    • Inventia Healthcare Limited is managing a nationwide voluntary recall of 13,567 bottles of chlorthalidone 25 mg tablets.
    • The Food and Drug Administration classified the ongoing action under its Class II risk level on September 17.

    What to watch next

    • Release of specific nationwide distribution locations for the impacted medication bottles
    • Further updates from the Food and Drug Administration regarding the enforcement report
    Sources used for this update (2)

    1. www.foxbusiness.com — Product Recalls
    2. www.newsbreak.com — Hurricane Polo makes 2nd landfall in Mexico as Category 1 storm - NewsBreak
    confidence 100%
13. 41d ago

    Nationwide Blood Pressure Medication Recall Underway

    Inventia Healthcare Limited is managing a nationwide voluntary recall of 13,567 bottles of chlorthalidone 25 mg tablets after the medication failed dissolution testing specifications. The Food and Drug Administration classified the ongoing action under its Class II risk level on September 17. The affected pills treat high blood pressure and are sometimes prescribed for patients managing heart failure, kidney disease, or cirrhosis of the liver. An enforcement report this month confirmed the Class II designation but did not detail specific nationwide distribution locations for the impacted medication.

    Why it matters

    Class II recalls indicate that use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health effects is remote. Chlorthalidone helps patients manage hypertension and related cardiovascular or renal conditions, making consistent potency and dissolution critical for effective treatment. Regulatory oversight ensures defective batches are removed from circulation to protect patients from subpotent or erratic drug release.

    What is confirmed

    • Inventia Healthcare Limited is conducting a nationwide voluntary recall of 13,567 bottles of chlorthalidone 25 mg tablets.
    • The recall was initiated after the medication failed dissolution testing specifications.
    • The Food and Drug Administration classified the ongoing action under its Class II risk level on September 17.
    • The affected pills treat high blood pressure and are sometimes prescribed for patients managing heart failure, kidney disease, or cirrhosis of the liver.
    • An enforcement report this month confirmed the Class II designation but did not detail specific nationwide distribution locations.

    What to watch next

    • Identification of specific nationwide distribution locations by the Food and Drug Administration or Inventia Healthcare Limited.
    • Further updates on the retrieval and disposal of the 13,567 recalled bottles.
    Sources used for this update (2)

    1. www.iheart.com — Blood Pressure Medication Recalled Nationwide - iHeart
    2. www.yahoo.com — Check your email: Notices sent regarding $309M Amazon returns settlement
    confidence 100%
14. 43d ago

    Nationwide Blood Pressure Medication Recall Enters Class II Risk Level

    Inventia Healthcare Limited is conducting a nationwide voluntary recall of 13,567 bottles of chlorthalidone 25 mg tablets after the medication failed dissolution testing specifications. The Food and Drug Administration classified the ongoing action under its Class II risk level on September 17. The affected pills treat high blood pressure and are sometimes prescribed for patients managing heart failure, kidney disease, or cirrhosis of the liver. An enforcement report this month confirmed the Class II designation but did not detail specific nationwide distribution locations for the impacted medication.

    Why it matters

    Blood pressure medication ranks among the most common treatments utilized across the United States. This regulatory action marks the second time this year that chlorthalidone tablets have faced a recall due to failures in standard dissolution testing. Dissolution failures can affect how the body absorbs the active pharmaceutical ingredient.

    What is confirmed

    • Inventia Healthcare Limited is voluntarily recalling 13,567 bottles of chlorthalidone 25 mg tablets nationwide.
    • The Food and Drug Administration classified the ongoing recall under its Class II risk level on September 17.
    • The affected pills are used to lower blood pressure and may have been prescribed to patients with heart failure, kidney disease, or cirrhosis of the liver.
    • This is the second time chlorthalidone tablets have been recalled this year due to dissolution test failures.
    • An FDA enforcement report this month designated the recall a Class II risk level.

    Still unconfirmed

    • The distribution locations of the recalled pills remain unspecified.

    What to watch next

    • Release of specific distribution locations or store-level details by the FDA or Inventia Healthcare Limited.
    • Further updates regarding the total number of bottles recovered or patient adverse events linked to the dissolution failures.
    Sources used for this update (3)

    1. www.newsbreak.com — Dengue fever surge in Florida shows the virus’ growing threat in the U.S. - NewsBreak
    2. www.newsbreak.com — Trump Accounts will auto-enroll children, potentially adding 60 million accounts: Treasury - NewsBreak
    3. flipboard.com — 13,000 bottles of blood pressure medication are being recalled nationwide: What to look out for
    confidence 100%
15. 45d ago

    Nationwide Blood Pressure Medication Recalled Under FDA Class II

    Inventia Healthcare Limited is voluntarily recalling 13,567 bottles of chlorthalidone 25 mg tablets nationwide because the medication failed to meet the Food and Drug Administration dissolution testing specifications. The Food and Drug Administration classified the ongoing recall under its Class II risk level on September 17. The affected pills are used to lower blood pressure and may have also been prescribed to patients with heart failure, kidney disease, or cirrhosis of the liver. This marks the second time chlorthalidone tablets have been recalled this year due to dissolution test failures.

    Why it matters

    Dissolution testing ensures that the correct amount of active drug enters the bloodstream within a specified time. When medications fail these tests, patients may receive too little or too much of the active ingredient, posing health risks. The Class II designation is the second-highest level of risk used by the Food and Drug Administration, indicating that use of the product may cause temporary or medically reversible adverse health consequences.

    What is confirmed

    • Inventia Healthcare Limited is voluntarily recalling 13,567 bottles of chlorthalidone 25 mg tablets nationwide.
    • The recall was triggered because the tablets failed to meet Food and Drug Administration dissolution testing specifications.
    • The Food and Drug Administration classified the ongoing recall as a Class II risk level on September 17.
    • Chlorthalidone tablets are used to treat high blood pressure and may be prescribed to those with heart failure, kidney disease, or liver cirrhosis.

    What to watch next

    • Further statements from Inventia Healthcare Limited regarding expanded recalls or affected lot numbers
    • Guidance from healthcare providers on whether patients should switch alternative medications
    Sources used for this update (11)

    1. The Hill — Blood pressure medication recalled nationwide under FDA’s Class II risk level
    2. WUSA9 — Blood pressure medication recalled nationwide after failing FDA dissolution testing
    3. Good Housekeeping — FDA Announces New Nationwide Blood Pressure Medication Recall
    4. newsnationnow.com — Blood pressure medication given Class II designation in recall update
    5. Newsday — Drug company recalls blood pressure medication chlorthalidone
    6. www.goodhousekeeping.com — FDA Announces New Nationwide Blood Pressure Medication Recall
    7. www.nbcchicago.com — FDA recalls more bottles of blood pressure medication – NBC ...
    8. ground.news — Blood pressure medication recalled nationwide under FDA’s ...
    9. www.yahoo.com — Blood Pressure Drug Recall Hits Nearly 14,000 Medicines in US Under FDA’s ‘Adverse Health Consequences’ Risk
    10. flipboard.com — FDA Updates Recalled Blood Pressure Medication to Second-Highest Level
    11. www.usatoday.com — Blood pressure medication recall. What patients need to know
    confidence 100%